nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—ERBB2—peripheral nervous system neoplasm	0.491	0.874	CbGaD
Lapatinib—ABCB1—peripheral nervous system neoplasm	0.0707	0.126	CbGaD
Lapatinib—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0288	0.135	CbGbCtD
Lapatinib—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0277	0.129	CbGbCtD
Lapatinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0201	0.0942	CbGbCtD
Lapatinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0201	0.0942	CbGbCtD
Lapatinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.014	0.0653	CbGbCtD
Lapatinib—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0132	0.0618	CbGbCtD
Lapatinib—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0121	0.0566	CbGbCtD
Lapatinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0121	0.0564	CbGbCtD
Lapatinib—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0116	0.0544	CbGbCtD
Lapatinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0112	0.0525	CbGbCtD
Lapatinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0086	0.0402	CbGbCtD
Lapatinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00802	0.0375	CbGbCtD
Lapatinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00788	0.0368	CbGbCtD
Lapatinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00538	0.0251	CbGbCtD
Lapatinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00515	0.0241	CbGbCtD
Lapatinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00472	0.0221	CbGbCtD
Lapatinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00322	0.0151	CbGbCtD
Lapatinib—Gefitinib—CHEK2—peripheral nervous system neoplasm	0.0029	0.892	CrCbGaD
Lapatinib—TAP1—trigeminal ganglion—peripheral nervous system neoplasm	0.000912	0.126	CbGeAlD
Lapatinib—PIK3C2B—Vindesine—Vincristine—peripheral nervous system neoplasm	0.000906	0.268	CbGdCrCtD
Lapatinib—TAP1—parotid gland—peripheral nervous system neoplasm	0.00086	0.119	CbGeAlD
Lapatinib—PIK3C2B—trigeminal ganglion—peripheral nervous system neoplasm	0.000856	0.118	CbGeAlD
Lapatinib—PIK3C2B—parotid gland—peripheral nervous system neoplasm	0.000808	0.112	CbGeAlD
Lapatinib—PI4KB—trigeminal ganglion—peripheral nervous system neoplasm	0.000624	0.0863	CbGeAlD
Lapatinib—ERBB4—brainstem—peripheral nervous system neoplasm	0.000589	0.0815	CbGeAlD
Lapatinib—PI4KB—parotid gland—peripheral nervous system neoplasm	0.000588	0.0814	CbGeAlD
Lapatinib—PIK3C2B—Vinorelbine—Vincristine—peripheral nervous system neoplasm	0.000572	0.169	CbGdCrCtD
Lapatinib—PIK3C2B—Podofilox—Etoposide—peripheral nervous system neoplasm	0.000571	0.169	CbGdCrCtD
Lapatinib—ERBB2—Podofilox—Etoposide—peripheral nervous system neoplasm	0.00047	0.139	CbGdCrCtD
Lapatinib—TAP1—cerebellum—peripheral nervous system neoplasm	0.000398	0.055	CbGeAlD
Lapatinib—PIK3C2B—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.000393	0.116	CbGdCrCtD
Lapatinib—PIK3C2B—cerebellum—peripheral nervous system neoplasm	0.000374	0.0517	CbGeAlD
Lapatinib—Gefitinib—ABCB1—peripheral nervous system neoplasm	0.000353	0.108	CrCbGaD
Lapatinib—ERBB2—cerebellum—peripheral nervous system neoplasm	0.000291	0.0402	CbGeAlD
Lapatinib—ERBB4—cerebellum—peripheral nervous system neoplasm	0.000291	0.0402	CbGeAlD
Lapatinib—PI4KB—cerebellum—peripheral nervous system neoplasm	0.000272	0.0376	CbGeAlD
Lapatinib—EGFR—cerebellum—peripheral nervous system neoplasm	0.000246	0.0341	CbGeAlD
Lapatinib—ERBB2—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000245	0.0725	CbGdCrCtD
Lapatinib—ERBB2—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000227	0.0671	CbGdCrCtD
Lapatinib—Angiopathy—Etoposide—peripheral nervous system neoplasm	0.00015	0.00119	CcSEcCtD
Lapatinib—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000149	0.00119	CcSEcCtD
Lapatinib—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.000149	0.00119	CcSEcCtD
Lapatinib—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000149	0.00118	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000148	0.00117	CcSEcCtD
Lapatinib—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000147	0.00117	CcSEcCtD
Lapatinib—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000147	0.00117	CcSEcCtD
Lapatinib—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000146	0.00116	CcSEcCtD
Lapatinib—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000146	0.00116	CcSEcCtD
Lapatinib—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000146	0.00116	CcSEcCtD
Lapatinib—Alopecia—Etoposide—peripheral nervous system neoplasm	0.000146	0.00116	CcSEcCtD
Lapatinib—Anaemia—Cisplatin—peripheral nervous system neoplasm	0.000145	0.00115	CcSEcCtD
Lapatinib—Renal failure acute—Epirubicin—peripheral nervous system neoplasm	0.000145	0.00115	CcSEcCtD
Lapatinib—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.000145	0.00115	CcSEcCtD
Lapatinib—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000144	0.00115	CcSEcCtD
Lapatinib—Infection—Vincristine—peripheral nervous system neoplasm	0.000144	0.00114	CcSEcCtD
Lapatinib—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000143	0.00114	CcSEcCtD
Lapatinib—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.000143	0.00114	CcSEcCtD
Lapatinib—Hot flush—Epirubicin—peripheral nervous system neoplasm	0.000143	0.00114	CcSEcCtD
Lapatinib—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000142	0.00113	CcSEcCtD
Lapatinib—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000142	0.00113	CcSEcCtD
Lapatinib—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000142	0.00113	CcSEcCtD
Lapatinib—Menopausal symptoms—Epirubicin—peripheral nervous system neoplasm	0.000142	0.00113	CcSEcCtD
Lapatinib—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000141	0.00112	CcSEcCtD
Lapatinib—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000141	0.00112	CcSEcCtD
Lapatinib—Leukopenia—Cisplatin—peripheral nervous system neoplasm	0.00014	0.00112	CcSEcCtD
Lapatinib—Asthenia—Melphalan—peripheral nervous system neoplasm	0.00014	0.00112	CcSEcCtD
Lapatinib—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.00014	0.00112	CcSEcCtD
Lapatinib—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.00014	0.00112	CcSEcCtD
Lapatinib—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.00014	0.00111	CcSEcCtD
Lapatinib—Back pain—Etoposide—peripheral nervous system neoplasm	0.000139	0.00111	CcSEcCtD
Lapatinib—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000139	0.0011	CcSEcCtD
Lapatinib—Anorexia—Vincristine—peripheral nervous system neoplasm	0.000138	0.0011	CcSEcCtD
Lapatinib—Cardiac failure—Epirubicin—peripheral nervous system neoplasm	0.000137	0.00109	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000137	0.00109	CcSEcCtD
Lapatinib—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000137	0.00109	CcSEcCtD
Lapatinib—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.000136	0.00108	CcSEcCtD
Lapatinib—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000136	0.00108	CcSEcCtD
Lapatinib—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000136	0.00108	CcSEcCtD
Lapatinib—Renal failure acute—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.00107	CcSEcCtD
Lapatinib—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000134	0.00106	CcSEcCtD
Lapatinib—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000134	0.00106	CcSEcCtD
Lapatinib—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.000134	0.00106	CcSEcCtD
Lapatinib—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.000134	0.00106	CcSEcCtD
Lapatinib—Anaemia—Etoposide—peripheral nervous system neoplasm	0.000133	0.00106	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000133	0.00105	CcSEcCtD
Lapatinib—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000133	0.00105	CcSEcCtD
Lapatinib—Hot flush—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.00105	CcSEcCtD
Lapatinib—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000132	0.00105	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000132	0.00105	CcSEcCtD
Lapatinib—Menopausal symptoms—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.00104	CcSEcCtD
Lapatinib—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000131	0.00104	CcSEcCtD
Lapatinib—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000131	0.00104	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.00013	0.00103	CcSEcCtD
Lapatinib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.00013	0.00103	CcSEcCtD
Lapatinib—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000129	0.00102	CcSEcCtD
Lapatinib—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000129	0.00102	CcSEcCtD
Lapatinib—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000128	0.00102	CcSEcCtD
Lapatinib—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000128	0.00102	CcSEcCtD
Lapatinib—Infection—Cisplatin—peripheral nervous system neoplasm	0.000127	0.00101	CcSEcCtD
Lapatinib—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000127	0.00101	CcSEcCtD
Lapatinib—Cardiac failure—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.00101	CcSEcCtD
Lapatinib—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000126	0.001	CcSEcCtD
Lapatinib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000126	0.001	CcSEcCtD
Lapatinib—Rash—Topotecan—peripheral nervous system neoplasm	0.000126	0.001	CcSEcCtD
Lapatinib—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000126	0.001	CcSEcCtD
Lapatinib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000126	0.001	CcSEcCtD
Lapatinib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000126	0.000998	CcSEcCtD
Lapatinib—Cough—Etoposide—peripheral nervous system neoplasm	0.000125	0.000997	CcSEcCtD
Lapatinib—Headache—Topotecan—peripheral nervous system neoplasm	0.000125	0.000995	CcSEcCtD
Lapatinib—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000125	0.000994	CcSEcCtD
Lapatinib—Rash—Tretinoin—peripheral nervous system neoplasm	0.000125	0.000994	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000125	0.000994	CcSEcCtD
Lapatinib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000125	0.000993	CcSEcCtD
Lapatinib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000125	0.000993	CcSEcCtD
Lapatinib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000125	0.000992	CcSEcCtD
Lapatinib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000124	0.000989	CcSEcCtD
Lapatinib—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000989	CcSEcCtD
Lapatinib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000124	0.000989	CcSEcCtD
Lapatinib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000124	0.000987	CcSEcCtD
Lapatinib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000124	0.000987	CcSEcCtD
Lapatinib—Constipation—Vincristine—peripheral nervous system neoplasm	0.000124	0.000984	CcSEcCtD
Lapatinib—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000984	CcSEcCtD
Lapatinib—Rash—Melphalan—peripheral nervous system neoplasm	0.000123	0.000981	CcSEcCtD
Lapatinib—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000123	0.00098	CcSEcCtD
Lapatinib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000123	0.000977	CcSEcCtD
Lapatinib—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000975	CcSEcCtD
Lapatinib—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000122	0.00097	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000122	0.000966	CcSEcCtD
Lapatinib—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000119	0.000949	CcSEcCtD
Lapatinib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000119	0.000944	CcSEcCtD
Lapatinib—Nausea—Topotecan—peripheral nervous system neoplasm	0.000119	0.000944	CcSEcCtD
Lapatinib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000118	0.000941	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000938	CcSEcCtD
Lapatinib—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000118	0.000936	CcSEcCtD
Lapatinib—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000118	0.000936	CcSEcCtD
Lapatinib—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000117	0.000932	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000117	0.000927	CcSEcCtD
Lapatinib—Infection—Etoposide—peripheral nervous system neoplasm	0.000117	0.000926	CcSEcCtD
Lapatinib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000116	0.000924	CcSEcCtD
Lapatinib—Nausea—Melphalan—peripheral nervous system neoplasm	0.000116	0.000924	CcSEcCtD
Lapatinib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000915	CcSEcCtD
Lapatinib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000115	0.00091	CcSEcCtD
Lapatinib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000114	0.000907	CcSEcCtD
Lapatinib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000114	0.000906	CcSEcCtD
Lapatinib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000902	CcSEcCtD
Lapatinib—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000112	0.000889	CcSEcCtD
Lapatinib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000111	0.000885	CcSEcCtD
Lapatinib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000111	0.000881	CcSEcCtD
Lapatinib—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000111	0.00088	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000111	0.000879	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000868	CcSEcCtD
Lapatinib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000859	CcSEcCtD
Lapatinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000108	0.000857	CcSEcCtD
Lapatinib—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000107	0.000848	CcSEcCtD
Lapatinib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000106	0.000845	CcSEcCtD
Lapatinib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000105	0.000831	CcSEcCtD
Lapatinib—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000104	0.000826	CcSEcCtD
Lapatinib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000824	CcSEcCtD
Lapatinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000103	0.00082	CcSEcCtD
Lapatinib—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000103	0.00082	CcSEcCtD
Lapatinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000103	0.000819	CcSEcCtD
Lapatinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000103	0.000817	CcSEcCtD
Lapatinib—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000102	0.000812	CcSEcCtD
Lapatinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000102	0.000811	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000101	0.000805	CcSEcCtD
Lapatinib—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000101	0.000804	CcSEcCtD
Lapatinib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000803	CcSEcCtD
Lapatinib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000799	CcSEcCtD
Lapatinib—Constipation—Etoposide—peripheral nervous system neoplasm	0.0001	0.000797	CcSEcCtD
Lapatinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000795	CcSEcCtD
Lapatinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	9.91e-05	0.000788	CcSEcCtD
Lapatinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	9.75e-05	0.000775	CcSEcCtD
Lapatinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	9.73e-05	0.000773	CcSEcCtD
Lapatinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	9.63e-05	0.000765	CcSEcCtD
Lapatinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	9.6e-05	0.000763	CcSEcCtD
Lapatinib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	9.6e-05	0.000762	CcSEcCtD
Lapatinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	9.56e-05	0.00076	CcSEcCtD
Lapatinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	9.54e-05	0.000758	CcSEcCtD
Lapatinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	9.54e-05	0.000758	CcSEcCtD
Lapatinib—Rash—Alitretinoin—peripheral nervous system neoplasm	9.48e-05	0.000753	CcSEcCtD
Lapatinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	9.47e-05	0.000752	CcSEcCtD
Lapatinib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	9.44e-05	0.00075	CcSEcCtD
Lapatinib—Headache—Alitretinoin—peripheral nervous system neoplasm	9.42e-05	0.000748	CcSEcCtD
Lapatinib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	9.35e-05	0.000743	CcSEcCtD
Lapatinib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	9.3e-05	0.000739	CcSEcCtD
Lapatinib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	9.28e-05	0.000737	CcSEcCtD
Lapatinib—Vomiting—Vincristine—peripheral nervous system neoplasm	9.21e-05	0.000732	CcSEcCtD
Lapatinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	9.19e-05	0.00073	CcSEcCtD
Lapatinib—Rash—Vincristine—peripheral nervous system neoplasm	9.13e-05	0.000726	CcSEcCtD
Lapatinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	9.12e-05	0.000725	CcSEcCtD
Lapatinib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	9.1e-05	0.000723	CcSEcCtD
Lapatinib—Headache—Vincristine—peripheral nervous system neoplasm	9.07e-05	0.000721	CcSEcCtD
Lapatinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	9.02e-05	0.000717	CcSEcCtD
Lapatinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	9e-05	0.000715	CcSEcCtD
Lapatinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	8.93e-05	0.00071	CcSEcCtD
Lapatinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	8.76e-05	0.000696	CcSEcCtD
Lapatinib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	8.68e-05	0.012	CbGeAlD
Lapatinib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	8.65e-05	0.000687	CcSEcCtD
Lapatinib—Nausea—Vincristine—peripheral nervous system neoplasm	8.6e-05	0.000684	CcSEcCtD
Lapatinib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	8.59e-05	0.000683	CcSEcCtD
Lapatinib—Asthenia—Etoposide—peripheral nervous system neoplasm	8.42e-05	0.000669	CcSEcCtD
Lapatinib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	8.42e-05	0.000669	CcSEcCtD
Lapatinib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	8.4e-05	0.000667	CcSEcCtD
Lapatinib—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	8.36e-05	0.000665	CcSEcCtD
Lapatinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	8.34e-05	0.000663	CcSEcCtD
Lapatinib—Pruritus—Etoposide—peripheral nervous system neoplasm	8.3e-05	0.00066	CcSEcCtD
Lapatinib—Alopecia—Epirubicin—peripheral nervous system neoplasm	8.18e-05	0.00065	CcSEcCtD
Lapatinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	8.14e-05	0.000647	CcSEcCtD
Lapatinib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	8.11e-05	0.000645	CcSEcCtD
Lapatinib—Rash—Cisplatin—peripheral nervous system neoplasm	8.08e-05	0.000642	CcSEcCtD
Lapatinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	8.07e-05	0.000641	CcSEcCtD
Lapatinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	8.06e-05	0.00064	CcSEcCtD
Lapatinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	8.03e-05	0.000638	CcSEcCtD
Lapatinib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	7.95e-05	0.000632	CcSEcCtD
Lapatinib—Back pain—Epirubicin—peripheral nervous system neoplasm	7.8e-05	0.000619	CcSEcCtD
Lapatinib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	7.77e-05	0.000618	CcSEcCtD
Lapatinib—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	7.74e-05	0.000615	CcSEcCtD
Lapatinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	7.72e-05	0.000613	CcSEcCtD
Lapatinib—Nausea—Cisplatin—peripheral nervous system neoplasm	7.61e-05	0.000605	CcSEcCtD
Lapatinib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	7.57e-05	0.000602	CcSEcCtD
Lapatinib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	7.5e-05	0.000596	CcSEcCtD
Lapatinib—Vomiting—Etoposide—peripheral nervous system neoplasm	7.46e-05	0.000593	CcSEcCtD
Lapatinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	7.46e-05	0.000593	CcSEcCtD
Lapatinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	7.45e-05	0.000592	CcSEcCtD
Lapatinib—Rash—Etoposide—peripheral nervous system neoplasm	7.4e-05	0.000588	CcSEcCtD
Lapatinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	7.39e-05	0.000587	CcSEcCtD
Lapatinib—Headache—Etoposide—peripheral nervous system neoplasm	7.35e-05	0.000584	CcSEcCtD
Lapatinib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	7.21e-05	0.000573	CcSEcCtD
Lapatinib—Back pain—Doxorubicin—peripheral nervous system neoplasm	7.21e-05	0.000573	CcSEcCtD
Lapatinib—Palpitations—Epirubicin—peripheral nervous system neoplasm	7.12e-05	0.000566	CcSEcCtD
Lapatinib—Cough—Epirubicin—peripheral nervous system neoplasm	7.03e-05	0.000559	CcSEcCtD
Lapatinib—Nausea—Etoposide—peripheral nervous system neoplasm	6.97e-05	0.000554	CcSEcCtD
Lapatinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	6.89e-05	0.000548	CcSEcCtD
Lapatinib—Myalgia—Epirubicin—peripheral nervous system neoplasm	6.86e-05	0.000545	CcSEcCtD
Lapatinib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	6.86e-05	0.000545	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	6.81e-05	0.000541	CcSEcCtD
Lapatinib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	6.67e-05	0.00053	CcSEcCtD
Lapatinib—Palpitations—Doxorubicin—peripheral nervous system neoplasm	6.59e-05	0.000524	CcSEcCtD
Lapatinib—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	6.58e-05	0.000523	CcSEcCtD
Lapatinib—Infection—Epirubicin—peripheral nervous system neoplasm	6.53e-05	0.000519	CcSEcCtD
Lapatinib—Cough—Doxorubicin—peripheral nervous system neoplasm	6.51e-05	0.000517	CcSEcCtD
Lapatinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	6.45e-05	0.000513	CcSEcCtD
Lapatinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	6.39e-05	0.000508	CcSEcCtD
Lapatinib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	6.35e-05	0.000504	CcSEcCtD
Lapatinib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	6.35e-05	0.000504	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	6.3e-05	0.000501	CcSEcCtD
Lapatinib—Anorexia—Epirubicin—peripheral nervous system neoplasm	6.27e-05	0.000498	CcSEcCtD
Lapatinib—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	6.09e-05	0.000484	CcSEcCtD
Lapatinib—Infection—Doxorubicin—peripheral nervous system neoplasm	6.05e-05	0.00048	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	5.99e-05	0.000476	CcSEcCtD
Lapatinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	5.97e-05	0.000474	CcSEcCtD
Lapatinib—Insomnia—Epirubicin—peripheral nervous system neoplasm	5.95e-05	0.000473	CcSEcCtD
Lapatinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	5.91e-05	0.00047	CcSEcCtD
Lapatinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	5.86e-05	0.000466	CcSEcCtD
Lapatinib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	5.8e-05	0.000461	CcSEcCtD
Lapatinib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.00046	CcSEcCtD
Lapatinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	5.72e-05	0.000454	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	5.68e-05	0.000451	CcSEcCtD
Lapatinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	5.67e-05	0.000451	CcSEcCtD
Lapatinib—Constipation—Epirubicin—peripheral nervous system neoplasm	5.62e-05	0.000447	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	5.54e-05	0.000441	CcSEcCtD
Lapatinib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	5.5e-05	0.000437	CcSEcCtD
Lapatinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	5.43e-05	0.000431	CcSEcCtD
Lapatinib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	5.38e-05	0.000427	CcSEcCtD
Lapatinib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000426	CcSEcCtD
Lapatinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	5.29e-05	0.00042	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.25e-05	0.000418	CcSEcCtD
Lapatinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	5.25e-05	0.000417	CcSEcCtD
Lapatinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.000414	CcSEcCtD
Lapatinib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	5.2e-05	0.000413	CcSEcCtD
Lapatinib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	4.98e-05	0.000395	CcSEcCtD
Lapatinib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	4.85e-05	0.000385	CcSEcCtD
Lapatinib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	4.81e-05	0.000382	CcSEcCtD
Lapatinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	4.72e-05	0.000375	CcSEcCtD
Lapatinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	4.65e-05	0.00037	CcSEcCtD
Lapatinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	4.5e-05	0.000358	CcSEcCtD
Lapatinib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	4.48e-05	0.000356	CcSEcCtD
Lapatinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	4.37e-05	0.000347	CcSEcCtD
Lapatinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	4.31e-05	0.000342	CcSEcCtD
Lapatinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	4.18e-05	0.000332	CcSEcCtD
Lapatinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	4.16e-05	0.000331	CcSEcCtD
Lapatinib—Rash—Epirubicin—peripheral nervous system neoplasm	4.15e-05	0.00033	CcSEcCtD
Lapatinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	4.14e-05	0.000329	CcSEcCtD
Lapatinib—Headache—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000327	CcSEcCtD
Lapatinib—Nausea—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.00031	CcSEcCtD
Lapatinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000307	CcSEcCtD
Lapatinib—Rash—Doxorubicin—peripheral nervous system neoplasm	3.84e-05	0.000305	CcSEcCtD
Lapatinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.83e-05	0.000305	CcSEcCtD
Lapatinib—Headache—Doxorubicin—peripheral nervous system neoplasm	3.81e-05	0.000303	CcSEcCtD
Lapatinib—ABCB1—cerebellum—peripheral nervous system neoplasm	3.79e-05	0.00523	CbGeAlD
Lapatinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	3.61e-05	0.000287	CcSEcCtD
Lapatinib—EGFR—Signaling by FGFR in disease—NRAS—peripheral nervous system neoplasm	2.85e-05	0.000338	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	2.85e-05	0.000338	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	2.82e-05	0.000335	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.81e-05	0.000333	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	2.8e-05	0.000332	CbGpPWpGaD
Lapatinib—EGFR—ErbB1 downstream signaling—AKT1—peripheral nervous system neoplasm	2.79e-05	0.000332	CbGpPWpGaD
Lapatinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—peripheral nervous system neoplasm	2.79e-05	0.000332	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	2.79e-05	0.000331	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	2.77e-05	0.000328	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.76e-05	0.000327	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PPP3R1—peripheral nervous system neoplasm	2.75e-05	0.000326	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.72e-05	0.000322	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—HRAS—peripheral nervous system neoplasm	2.66e-05	0.000315	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—NRAS—peripheral nervous system neoplasm	2.64e-05	0.000313	CbGpPWpGaD
Lapatinib—EGFR—Direct p53 effectors—TP53—peripheral nervous system neoplasm	2.63e-05	0.000312	CbGpPWpGaD
Lapatinib—TAP1—Immune System—HRAS—peripheral nervous system neoplasm	2.6e-05	0.000308	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—AKT1—peripheral nervous system neoplasm	2.59e-05	0.000308	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—NRAS—peripheral nervous system neoplasm	2.59e-05	0.000308	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by NGF—AKT1—peripheral nervous system neoplasm	2.55e-05	0.000303	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	2.55e-05	0.000303	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.54e-05	0.000301	CbGpPWpGaD
Lapatinib—EGFR—Disease—PPP3R1—peripheral nervous system neoplasm	2.54e-05	0.000301	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	2.52e-05	0.000299	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	2.5e-05	0.000297	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	2.5e-05	0.000296	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	2.48e-05	0.000294	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.44e-05	0.000289	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.43e-05	0.000289	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.43e-05	0.000289	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NCAM1—peripheral nervous system neoplasm	2.43e-05	0.000288	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	2.39e-05	0.000284	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.36e-05	0.00028	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	2.35e-05	0.000279	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.32e-05	0.000276	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—CASP3—peripheral nervous system neoplasm	2.32e-05	0.000275	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—ERBB2—peripheral nervous system neoplasm	2.31e-05	0.000274	CbGpPWpGaD
Lapatinib—TAP1—Immune System—AKT1—peripheral nervous system neoplasm	2.29e-05	0.000272	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.29e-05	0.000272	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	2.27e-05	0.00027	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.26e-05	0.000268	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MET—peripheral nervous system neoplasm	2.25e-05	0.000267	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.25e-05	0.000267	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	2.25e-05	0.000267	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	2.24e-05	0.000265	CbGpPWpGaD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	2.24e-05	0.000265	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	2.23e-05	0.000264	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—PTPN11—peripheral nervous system neoplasm	2.22e-05	0.000263	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—HRAS—peripheral nervous system neoplasm	2.22e-05	0.000263	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.22e-05	0.000263	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	2.21e-05	0.000262	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.2e-05	0.000261	CbGpPWpGaD
Lapatinib—EGFR—Disease—ENO2—peripheral nervous system neoplasm	2.2e-05	0.000261	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—PTPN11—peripheral nervous system neoplasm	2.19e-05	0.000259	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	2.18e-05	0.000259	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.17e-05	0.000258	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.17e-05	0.000257	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.12e-05	0.000251	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	2.11e-05	0.000251	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.09e-05	0.000248	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—PTPN11—peripheral nervous system neoplasm	2.08e-05	0.000247	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	2.08e-05	0.000247	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—HRAS—peripheral nervous system neoplasm	2.08e-05	0.000247	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	2.08e-05	0.000247	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	2.08e-05	0.000247	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	2.07e-05	0.000245	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.06e-05	0.000245	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	2.05e-05	0.000243	CbGpPWpGaD
Lapatinib—ERBB2—Disease—PTPN11—peripheral nervous system neoplasm	2.05e-05	0.000243	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	2.05e-05	0.000243	CbGpPWpGaD
Lapatinib—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	2.05e-05	0.000243	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	2.04e-05	0.000242	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.03e-05	0.000241	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GNS—peripheral nervous system neoplasm	2.03e-05	0.000241	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.02e-05	0.00024	CbGpPWpGaD
Lapatinib—ERBB4—Disease—PTPN11—peripheral nervous system neoplasm	2.02e-05	0.000239	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	1.99e-05	0.000236	CbGpPWpGaD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.98e-05	0.000234	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	1.98e-05	0.000234	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—HRAS—peripheral nervous system neoplasm	1.97e-05	0.000234	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	1.97e-05	0.000233	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—AKT1—peripheral nervous system neoplasm	1.96e-05	0.000232	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	1.95e-05	0.000231	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—NRAS—peripheral nervous system neoplasm	1.94e-05	0.00023	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.93e-05	0.000229	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.93e-05	0.000229	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—HRAS—peripheral nervous system neoplasm	1.93e-05	0.000229	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	1.93e-05	0.000229	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.92e-05	0.000228	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.92e-05	0.000228	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IFNB1—peripheral nervous system neoplasm	1.9e-05	0.000226	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—HRAS—peripheral nervous system neoplasm	1.9e-05	0.000225	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	1.87e-05	0.000222	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	1.85e-05	0.000219	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—PTPN11—peripheral nervous system neoplasm	1.84e-05	0.000218	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—AKT1—peripheral nervous system neoplasm	1.84e-05	0.000218	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	1.84e-05	0.000218	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	1.84e-05	0.000218	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	1.82e-05	0.000216	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	1.81e-05	0.000214	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.81e-05	0.000214	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	1.8e-05	0.000213	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.78e-05	0.000212	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	1.78e-05	0.000211	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.78e-05	0.000211	CbGpPWpGaD
Lapatinib—EGFR—Disease—SLC2A1—peripheral nervous system neoplasm	1.77e-05	0.00021	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	1.77e-05	0.00021	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GNS—peripheral nervous system neoplasm	1.76e-05	0.000209	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—NRAS—peripheral nervous system neoplasm	1.76e-05	0.000208	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—AKT1—peripheral nervous system neoplasm	1.74e-05	0.000206	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.73e-05	0.000205	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—ERBB2—peripheral nervous system neoplasm	1.73e-05	0.000205	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—AKT1—peripheral nervous system neoplasm	1.7e-05	0.000202	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.69e-05	0.0002	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NME1—peripheral nervous system neoplasm	1.69e-05	0.0002	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.68e-05	0.000199	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.67e-05	0.000199	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.65e-05	0.000196	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—ERBB2—peripheral nervous system neoplasm	1.65e-05	0.000195	CbGpPWpGaD
Lapatinib—PIK3C2B—Metabolism—AKT1—peripheral nervous system neoplasm	1.64e-05	0.000194	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	1.63e-05	0.000193	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—COX2—peripheral nervous system neoplasm	1.62e-05	0.000193	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.61e-05	0.000191	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.61e-05	0.000191	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.6e-05	0.00019	CbGpPWpGaD
Lapatinib—ERBB4—Disease—ERBB2—peripheral nervous system neoplasm	1.59e-05	0.000189	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.58e-05	0.000188	CbGpPWpGaD
Lapatinib—PI4KB—Metabolism—AKT1—peripheral nervous system neoplasm	1.58e-05	0.000187	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	1.57e-05	0.000186	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	1.53e-05	0.000182	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	1.51e-05	0.000179	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.48e-05	0.000175	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HGF—peripheral nervous system neoplasm	1.47e-05	0.000174	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.47e-05	0.000174	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.46e-05	0.000173	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.46e-05	0.000173	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	1.45e-05	0.000172	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.43e-05	0.00017	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.42e-05	0.000168	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—HRAS—peripheral nervous system neoplasm	1.42e-05	0.000168	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.41e-05	0.000168	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.41e-05	0.000168	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.4e-05	0.000166	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	1.4e-05	0.000166	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.33e-05	0.000158	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—NRAS—peripheral nervous system neoplasm	1.33e-05	0.000158	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—NRAS—peripheral nervous system neoplasm	1.31e-05	0.000156	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.31e-05	0.000155	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.29e-05	0.000153	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—HRAS—peripheral nervous system neoplasm	1.29e-05	0.000152	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.26e-05	0.00015	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.25e-05	0.000149	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—NRAS—peripheral nervous system neoplasm	1.25e-05	0.000149	CbGpPWpGaD
Lapatinib—ERBB2—Disease—NRAS—peripheral nervous system neoplasm	1.23e-05	0.000146	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	1.23e-05	0.000146	CbGpPWpGaD
Lapatinib—ERBB4—Disease—NRAS—peripheral nervous system neoplasm	1.21e-05	0.000144	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.17e-05	0.000139	CbGpPWpGaD
Lapatinib—ERBB2—Disease—MYC—peripheral nervous system neoplasm	1.15e-05	0.000136	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.14e-05	0.000135	CbGpPWpGaD
Lapatinib—ERBB4—Disease—MYC—peripheral nervous system neoplasm	1.13e-05	0.000134	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.12e-05	0.000132	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.11e-05	0.000131	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.09e-05	0.000129	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PTPN11—peripheral nervous system neoplasm	1.07e-05	0.000127	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	1.07e-05	0.000126	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.06e-05	0.000126	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	1.04e-05	0.000123	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.04e-05	0.000123	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.03e-05	0.000122	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.01e-05	0.00012	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.98e-06	0.000118	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.92e-06	0.000118	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTPN11—peripheral nervous system neoplasm	9.9e-06	0.000117	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	9.78e-06	0.000116	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HRAS—peripheral nervous system neoplasm	9.76e-06	0.000116	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HRAS—peripheral nervous system neoplasm	9.61e-06	0.000114	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	9.51e-06	0.000113	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	9.44e-06	0.000112	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	9.29e-06	0.00011	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—HRAS—peripheral nervous system neoplasm	9.17e-06	0.000109	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	9.05e-06	0.000107	CbGpPWpGaD
Lapatinib—ERBB2—Disease—HRAS—peripheral nervous system neoplasm	9.01e-06	0.000107	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	9.01e-06	0.000107	CbGpPWpGaD
Lapatinib—ERBB4—Disease—HRAS—peripheral nervous system neoplasm	8.87e-06	0.000105	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	8.74e-06	0.000104	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	8.71e-06	0.000103	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.62e-06	0.000102	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—AKT1—peripheral nervous system neoplasm	8.62e-06	0.000102	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.59e-06	0.000102	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.49e-06	0.000101	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—AKT1—peripheral nervous system neoplasm	8.49e-06	0.000101	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ERBB2—peripheral nervous system neoplasm	8.48e-06	0.000101	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	8.47e-06	0.0001	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.1e-06	9.61e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—AKT1—peripheral nervous system neoplasm	8.1e-06	9.6e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	8.04e-06	9.54e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.03e-06	9.53e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	7.98e-06	9.47e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—AKT1—peripheral nervous system neoplasm	7.95e-06	9.44e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.91e-06	9.38e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	7.85e-06	9.31e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—AKT1—peripheral nervous system neoplasm	7.84e-06	9.29e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	7.83e-06	9.29e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—ERBB2—peripheral nervous system neoplasm	7.83e-06	9.28e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7.78e-06	9.22e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.67e-06	9.1e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	7.56e-06	8.97e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.49e-06	8.88e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	7.38e-06	8.75e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.15e-06	8.48e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	7.06e-06	8.37e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.93e-06	8.22e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	6.91e-06	8.2e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	6.87e-06	8.15e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	6.78e-06	8.05e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.6e-06	7.82e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.5e-06	7.71e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NRAS—peripheral nervous system neoplasm	6.45e-06	7.65e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.31e-06	7.48e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.21e-06	7.37e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	6.17e-06	7.32e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	6.05e-06	7.18e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	6.02e-06	7.14e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NRAS—peripheral nervous system neoplasm	5.95e-06	7.06e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	5.72e-06	6.79e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.57e-06	6.61e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MYC—peripheral nervous system neoplasm	5.55e-06	6.58e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.49e-06	6.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.48e-06	6.5e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.16e-06	6.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.97e-06	5.9e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	4.83e-06	5.73e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HRAS—peripheral nervous system neoplasm	4.72e-06	5.6e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.61e-06	5.47e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.56e-06	5.41e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	4.55e-06	5.39e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—HRAS—peripheral nervous system neoplasm	4.36e-06	5.17e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.17e-06	4.94e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—AKT1—peripheral nervous system neoplasm	4.17e-06	4.94e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.88e-06	4.61e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—AKT1—peripheral nervous system neoplasm	3.85e-06	4.56e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	3.71e-06	4.4e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	3.64e-06	4.32e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.19e-06	3.78e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.05e-06	3.62e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.69e-06	3.19e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	2.15e-06	2.56e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	1.87e-06	2.21e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	1.67e-06	1.98e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.63e-06	1.93e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1e-06	1.19e-05	CbGpPWpGaD
